Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.

Hepatology (Baltimore, Md.) - 1 Aug 2002

Yang Huiling, Westland Christopher E, Delaney William E, Heathcote Elizabeth J, Ho Victoria, Fry John, Brosgart Carol, Gibbs Craig S, Miller Michael D, Xiong Shelly

Abstract excerpt

Current therapies for chronic hepatitis B virus (HBV) infection do not provide adequate long-term control of viral replication in the majority of patients. Monotherapy with nucleoside analogs, such as lamivudine and famciclovir, is effective for short periods but results in the emergence of drug-resistant HBV in a substantial number of patients within 1 year of therapy. Adefovir dipivoxil (ADV) has demonstrated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA-Directed DNA Polymerase

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Liver Neoplasms

Share to Organophosphonates

Share to Viral Load

Source

Identifiers

PMID: 12143057
DOI: 10.1053/jhep.2002.34740

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.PMID 12143057Read ↗

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.Semantic proximity Read ↗

Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy.Semantic proximity Read ↗

Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil.Semantic proximity Read ↗

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.Semantic proximity Read ↗

Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.Semantic proximity Read ↗

Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].Semantic proximity Read ↗

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.Semantic proximity Read ↗

Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.Semantic proximity Read ↗

[Resistance to adefovir in patients with chronic hepatitis B].Semantic proximity Read ↗

Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates.Semantic proximity Read ↗

Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.